Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on ...
Moderna beats Q3 forecasts as cost-cutting offsets weaker COVID vaccine sales and new mRNA cancer trials advance.
The boss of AstraZeneca (AZN.L) has confirmed plans to invest $50bn in the US by 2030, emphasising the importance of domestic manufacturing and research to ensure “health sovereignty” and supply chain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback